|
Oral, Head and Neck Cancer Screenings Can Save Lives (Medical News - 24/04/2008)
When diagnosed early, oral, head and neck cancers can be easily treated, without significant
complications. Pennsylvania Hospital will offer free screenings for oral, head and neck cancer
on Thursday, April 24 at the Center for Head and Neck Surgery at 811 Spruce Street, as part of
oral, head and neck cancer awareness week. When diagnosed early, oral, head and neck cancers can be easily treated, without significant
complications. Pennsylvania Hospital will offer free screenings for oral, head and neck cancer
on Thursday, April 24 at the Center for Head and Neck Surgery.
Take Philadelphia resident Carol Jessup for example. Soon after losing a friend to throat
cancer, Ms. Jessup was diagnosed with throat cancer herself, after complaining of pain to her
ear, nose and throat specialist. A fearless adventurer, Ms. Jessup’s impending trip to Machu Pichu and the Galapagos Islands
had to be cancelled and replaced with cancer treatment. Jessup is a former engineer and
certified project manager with IBM for 20 years. She had retired just five months before the
diagnosis. “Had my friend not recently gone through throat cancer, I may never have brought it up to my
doctor,” says Jessup of her throat pain. “We’re not conditioned to think that a sore throat can
be cancer.”
Oral, head and neck cancers are most common among those who smoke, chew tobacco and
consume excessive amounts of alcohol. More than 85 percent of head and neck cancers are
related to tobacco use, while others may have a relationship to viral causes such as HPV and
Epstein-Barr Virus. Jessup’s treatment included six weeks of chemotherapy, followed by seven weeks of radiation
treatment to shrink the tumor. She then had neck surgery to remove the remaining affected
lymph nodes on the right side of her neck. Her cancer treatment plan and neck surgery was guided by Jason G. Newman, MD, head and
neck surgeon at Pennsylvania Hospital. “Carol’s case was one of our easier ones to treat. Her
cancer was caught early and treatment immediately followed, says Dr. Newman. “Head and
neck cancers can spread quickly, and many people dismiss the symptoms as being something
other than cancer.” Jessup is back to normal now- with only a few reminders of her surgery. She often has dry
mouth due to a loss of saliva glands during radiation. Subsequent cat scans and PET scans
have shown the area to be cancer-free. Since surgery, Jessup has made the trip to the Galalopogos Islands, Machu Picchu, Buenos
Aires and Patagonia-- and is planning her second trip to Australia and Southeast Asia.
[Back]
Spit Test Spots Head and Neck Cancer. Researchers Also Working on Oral Swab Test for Lung
Cancer ( WebMD Medical News- 14/04/2008)
Researchers have developed a DNA spit test to detect the earliest signs of head and neck
cancer, when it is more curable, and they say it could be available by the end of the year. Also
in the works -- though not as far along -- is an oral swab test to gauge whether someone is at
increased risk of developing lung cancer. If it pans out in future research, the swab test could also be used to predict who has a high
probability of developing head and neck cancer and other tobacco-related cancers, the
researchers say.
More than 40,000 Americans are diagnosed with head and neck cancer annually and about
12,000 die of it. A total of 215,020 Americans will be diagnosed with lung cancer in 2008, and it
will kill 161,840, according to the American Cancer Society (ACS). Both new tests were discussed at the annual meeting of the American Association for Cancer
Research.
"Living Like Hell' Seema Sethi, MD, tells WebMD that she "jumped into research to find a test to pick up head
and neck cancer earlier" after losing her dad to a tobacco-related cancer. Sethi is a specialist
in otolaryngology-head and neck surgery at Henry Ford Hospital in Detroit.
"Everyone knows smoking and alcohol are associated with head and neck cancer, but no one
knows who's going to get it," she says. Currently, most cases are diagnosed in advanced stages, when prognosis is poor, Sethi says.
"Despite the best of treatments, outcomes are not as good as if it was picked up earlier," she
says.
Head and neck cancer is one of the most horrendous of diagnoses. "You have to chop off part
of the patient's face. They often can't swallow or eat solid food. There's a lot of mouth odor. So
even if you're living, you're living like hell," Sethi says.
Gene Test Predicts Head and Neck Cancer
Because the development of the disease in people at high risk, such as smokers, takes many
years, Sethi reasoned that this "window" period offered an opportunity for early screening.
She came up with the idea of looking for two genes -- PMAIP1 and PTPN1 -- that are associated
with head and neck cancer. Abnormalities in either gene signal the cancer.
The researchers took saliva samples from 27 patients with head and neck cancer and 10
healthy people without cancer. "Patients just spit in a cup," Sethi says. The researchers extracted DNA from the samples and analyzed it.
"Lo and behold, we could completely separate out the cancer patients from the normal
non-cancer healthy people," she says. Sethi says the next step will be to validate the test in people who come in for head and neck
screening because "they are a smoker, have a family history, or other reasons. By the end of
the year, we hope to have an early test for head and neck cancer," she says.
[Back]
Race, Gender Affect Laryngeal Cancer Survival-
(HealthDay- 20/12/2007)
A patient's sex and race, along with the type of treatment they receive, can impact their survival after a diagnosis of advanced laryngeal cancer, say U.S. researchers.
They analyzed data from a national cancer registry on more than 7,000 patients diagnosed with advanced laryngeal cancer between 1995 and 1998.Of those patients, 53.6 percent had a total laryngectomy (removal of the larynx), 30.6 percent had radiation therapy (radiotherapy) alone, and 15.8 percent had combined chemotherapy and radiotherapy.
"Controlling for the other included factors, the radiotherapy and chemo-radiotherapy groups had lower odds of survival than did the total laryngectomy group. The increased risk associated with death is approximately 30 percent for the chemo-radiotherapy group and 60 percent for the radiotherapy group," wrote study authors Dr. Amy Y. Chen, of Emory University and the American Cancer Society, and Dr. Michael Halpern, of the American Cancer Society.
They also found that men were less likely to survive than women; patients with stage IV disease were less likely to survive than those with stage III disease; black patients were more likely to die than white patients; and uninsured patients or those with Medicaid, Medicare or other government health plan coverage were more likely to die than those with private health insurance.
"We do not believe that insurance status in this analysis represents differential
treatment or quality of care for patients with advanced laryngeal cancer. Rather, insurance status is likely a proxy for multiple medical issues, including usual source of medical care, participation in screening and preventive care activities and exposure to related risk factors, including alcohol and/or tobacco use and poor diet, all of which can influence overall survival," the study authors wrote.
"In conclusion, this analysis demonstrates that total laryngectomy yields the highest likelihood of survival for patients with advanced laryngeal cancer," the researchers added.
The study was published in the December issue of the Archives of Otolaryngology -- Head and Neck Cancer.
[Back]
New radiation therapy for head and neck cancer shows promising results-
(ANI- 18/08/2007)
Scientists have devised a new radiation therapy for head and neck cancer. A Phase I/II trial conducted at Helsinki University Hospital, Finland found that
most head-and-neck cancers that recur locally after prior full-dose conventional radiation therapy respond to Boron Neutron Capture Therapy (BNCT).
The scientific director of the research program, professor Heikki Joensuu, University of Helsinki, considers the results clinically significant and very interesting. They open a new field for BNCT, since thus far BNCT has been evaluated only in the treatment of some brain tumours.
The follow-up results of 12 patients diagnosed with cancer of the head-and-neck and treated in a prospective clinical tria. All patients had cancer of the head-and-neck that had recurred locally after surgery and conventional radiation therapy. Ten out of the 12 patients had substantial tumour shrinkage following BNCT, and in 7 cases the tumour disappeared completely. Adverse effects of treatment were moderate and resembled those of conventional radiation therapy.
Boron neutron capture therapy (BNCT) is a form of targeted radiation treatment for cancer. It is still considered experimental. In this method a boron-containing compound (boronophenylalanine) is first infused into a peripheral vein, following which the compound accumulates in cancer tissue. Cancer is subsequently irradiated with neutrons obtained from a nuclear reactor, which causes boron atoms to split within the cancerous tissue as a result from a boron neutron capture reaction. The resulting smaller particles cause a large radiation effect within the tumour tissue, which destroys cancer cells.
The technique allows targeting of a high dosage of radiation to the tumour while allowing sparing of the adjacent normal tissues from the highest doses of radiation. Boron-mediated targeting of radiation allows treatment of patients who can no longer be treated with conventional radiation therapy. BNCT is administered as single one-day treatment that may be repeated.
Boneca Corporation's clinical research program includes also a phase I/II study that evaluates BNCT in the treatment of primary glioblastoma (a highly malignant brain tumour) and another clinical trial that assesses safety and efficacy of BNCT in the treatment of glioblastomas and anaplastic astrocytomas (a type of brain tumour) that have recurred after conventional radiation therapy.
"Our plan is to investigate BNCT in the treatment of cancers located elsewhere in the body that cannot be effectively managed by any known treatment," said professor Heikki Joensuu.
"The current treatment is a result of a long period of research, a proof of academic expertise, and a model for effective collaboration between Helsinki University Central Hospital, University of Helsinki, VTT Technical Research Centre of Finland, and the company", said Boneca Corporation's managing director Markku Pohjola.
The research reported in the International Journal of Radiation Oncology, Biology and Physics. (ANI)
[Back]
Fruit compound fights head and neck cancer-
(Reuters- 16/10/2007)
Lupeol, a compound in fruits like mangoes, grapes and strawberries, appears to be effective in killing and curbing the spread of cancer cells in the head and neck, a study in Hong Kong has found.
An experiment with mice showed lupeol worked most effectively with chemotherapy drugs and had almost no side effects, scientists at the University of Hong Kong said in a report published in the September issue of the journal Cancer Research.
"It can suppress the movement of cancer cells and suppress their growth and it is found to be even more effective than conventional drugs (eg. cisplatin)," said Anthony Yuen, a professor at the University of Hong Kong's surgery department.
"It's even more effective if we combine it with chemotherapy drugs, and has very little side effects," he said.
The team plans another round of animal test and hopes to proceed eventually to human clinical trials, though it would not commit itself to a timeframe.
Head and neck cancers involve cancers of the nose, oral cavity, throat, voice box, thyroid and salivary glands and they more commonly afflict Asians than Westerners.
Some of the risk factors include smoking, excessive alcohol consumption, chewing betel nut and diets rich in preserved foods, like salted fish.
Such cancers are difficult to treat. Fifty percent of victims are typically diagnosed in advanced stages, when cure rates would be so low they would be considered inoperable.
Surgeries on the head and neck are always difficult because they involve the removal of large areas of diseased skin and soft tissues and surgeons need to first figure out how to cover up these open wounds before they can try to excise the tumors.
Yuen said lupeol - also found in vegetables, olive seed, figs and saw palmeto - appeared to block a natural protein NFkB, which helps cells repair and grow, even cancer cells.
In the experiment, lupeol was given to mice infected with malignant head and neck cancer cells.
"From the animal models, not only did it suppress the spread, the tumor got smaller. Compared to conventional drugs, lupeol reduced the size of the tumor far faster," said Terence Lee, another member of the research team.
"Conventional drugs made the mice a lot thinner, but lupeol mice retained their bulk." Emaciation is usually viewed as a bad sign in the fight against cancer.
Yuen hopes lupeol can be applied to other cancers that are similarly dependent on the NFkB protein to grow and spread.
"It may be possible to use (lupeol) in other cancers because it is able to suppress the NFkB protien, which is activated in many cancers like prostate cancer, breast cancer, liver cancer," Yuen said.
[Back]
At the Dentist’s: Vicious Cycle of Gum Disease, Bone Loss and Cancer (NICHOLAS BAKALAR -
22/05/2007)
The bone loss caused by gum disease is associated with an increased risk for tongue cancer,
and the more the bone loss, the greater the risk, researchers report. Scientists evaluated
bone loss around the teeth in 51 men with newly diagnosed tongue cancer and in 54 men
without the diagnosis. X-rays were taken of the men’s jaws, and a radiologist who did not
know the cancer status of the men measured the amount of bone loss. The study took place
from 1999 to 2005. After adjusting for smoking status, sex, race and ethnicity, number of cavities, crowns, fillings
and missing teeth, the researchers calculated that for every one millimeter of bone loss, the
risk of tongue cancer increases more than fivefold. Chronic infection, the authors write in the May issue of The Archives of Otolaryngology: Head &
Neck Surgery, can play a role in cancer, either directly by the effect of the toxic products of
micro-organisms, or indirectly by inflammation that stimulates the formation of tumors.
“I was surprised by the magnitude of the effect,” said Frank A. Scannapieco, the senior author
and a professor of oral biology at the School of Dental Medicine at the State University of New
York at Buffalo. But, he added, “There have to be more population-based studies to support
these conclusions.” Although chronic gum disease was the only oral variable significantly associated with oral
cancer, the authors acknowledged that the number of people in the study was small and that
the diagnoses of periodontal disease were made from X-rays rather than direct measurement.
[Back]
Betel
quid chewing increases pharyngeal cancer risk( Reuters- 14/12/2006)
Betel quid chewing is a strong independent risk factor for pharyngeal
cancer (cancer of the back of the throat), but not laryngeal cancer
(cancer of the voice box), according to findings published in the
International Journal of Cancer. Chewing betel quid, which consists of
betel leaf from the Piper betle vine, is popular in many parts of Asia.
Betel quid is chewed for its stimulant effects, to satisfy hunger and as a
social and cultural practice.
"The risks of betel quid chewing with or without tobacco, alcohol
drinking and cigarette smoking have been well explored in the oral cavity
but not in the pharynx and larynx," Dr. Ying-Chin Ko, of National
Health Research Institutes, Taiwan, and colleagues write. The
investigators therefore examined 148 men with pharyngeal cancer, 128 men
with laryngeal cancer, and 255 men without either cancer who served as
"controls."
Betel quid chewing was significantly and independently associated with the
risk of pharyngeal cancer, increasing the risk by nearly eight-fold.
However, no significant association was observed between betel quid
chewing and laryngeal cancer. Those who consumed more than 20 quid a day
or swallowed the betel quid juice had an even high risk -- the
investigators observed a synergistic effect of these risk factors for both
pharyngeal and laryngeal cancer.
The quantity of exposure and the direct contact of the carcinogen to the
mucus membrane appear to enhance the carcinogenic process, Ko and
colleagues suggest. "Further studies to explore the associations
between betel quid chewing and cancers of other sites of the digestive
tract, for example, the esophagus and stomach, and the effects on other
systems of humans are necessary."
[Back]
Calls
for checks on mouth cancer-(Yahoo News- 15/12/2005)
People who smoke and drink are 30 times more likely to get oral cancer. A
woman who was diagnosed with mouth cancer is backing calls for people to
examine themselves for possible signs of the disease. Lorraine Bass, 36,
from Denbighshire, needed major surgery on her tongue after a lump was
found to be a tumour. Doctors said her life was saved because she had the
lump checked early.
Mrs Bass was treated at Glan Clwyd Hospital, Rhyl, which is holding a
drop-in screening clinic on Tuesday as part of Mouth Cancer Awareness
Week. The campaign, run by the British Dental Health Foundation,
highlights how picking up early signs of the condition, in the same way
people check for breast or testicular cancer, is the best way for them to
be on guard. Mrs Bass said: "Obviously early diagnosis is crucial.
Mouth cancer is an insidious illness and it will just take your life.
"You have to check. By checking you can catch it early and stay alive
for your loved ones." About 4,300 new cases of oral cancer are
diagnosed in the UK each year. Mrs Bass, a mother-of-two who does not
smoke, said the first sign she had of the trouble was in October 2002 when
she was at college. She said: "I was having lunch and I bit the
tumour. I didn't realise it was a tumour at the time, I thought it was my
tongue. It was extremely painful - I almost went through the roof.
"But I'm not one for going to doctor very much if I can help it. I
just assumed it would heal. "About two weeks later, the same thing
happened. I thought I'd re-bitten the cut area." She said she bought
some products from a chemist store and tried to treat what she still
thought was the cut on her tongue before going to see her GP, who
prescribed some tablets.
When she went back two weeks later, she saw a different GP who recommended
that they had her tongue checked by a specialist. Mrs Bass went to Glan
Clwyd, where a consultant diagnosed the cancer. "I was shocked
because I really had it stuck in my head that it was a mouth ulcer. I was
told I was diagnosed quite early. Unfortunately, there is always the fear
of it returning."
She underwent 14 hours of surgery, which involved cutting away part of her
tongue and rebuilding it with a flap of skin from her forearm. Mrs Bass
said doctors had been unable to explain why she contracted the disease
when, as a non-smoker and a light drinker, she was not in a high-risk
category. The ratio of women to men suffering with mouth cancer has
increased by a third over the last 10 years, though men are still twice as
likely to develop the condition.
The main risk factors of mouth cancer are smoking and drinking alcohol to
excess, and people who do both are up to 30 times more likely to develop
mouth cancer. The drop in screening clinic at the hospital on Tuesday
afternoon is open to anyone who is concerned they may be experiencing
symptoms of the disease. Dr Nigel Carter, chief executive of the British
Dental Health Foundation, said: "Self examination is now the norm for
breast cancer and testicular cancer - it needs to be the same for mouth
cancer." The Mouth Cancer Awareness Week 2005 theme is "It Could
Be You" to highlight how the condition can strike anyone at any time.
There are 4,990 new mouth cancer patients a year. Mouth cancer is rising
among young people and women. It is twice as common as cervical or
testicular cancer and is the sixth most common globally. A third of
patients with the disease die
Symptoms include:-
An ulcer that does not heal over three to four weeks
Any unexplained red or white patches in the mouth
Unexplained loss of teeth
Unexplained numbness of upper, or lower lip, or the tongue
Unexplained nose bleed from one side
Unexplained bleeding from the mouth
Persistent one sided sore throat
Persistent earache and sore
throat
Neck lump that does not go away
[Back]
Strategy
Helps Tailor Head, Neck Cancer Treatment (HealthDay News-30/08/2005)
Scientists have discovered a way to
determine which head and neck cancer patients would benefit from
additional drug treatment during radiation therapy. Some tumors that have
low concentrations of oxygen, or hypoxia, are resistant to radiation
therapy, explain researchers from Aarhus University Hospital in Denmark. A
drug called nimorazole can help in treating these tumors, but up to now
there's been no way to identify people who would benefit from the drug.
Reporting in this week's Lancet Oncology, the Danish team studied whether
patients' reaction to nimorazole could be predicted by measuring their
blood for osteopontin, a protein associated with tumors lacking oxygen.
They found that patients with high concentrations of the protein who
received a placebo did poorly compared with patients who received the
drug. "This finding might help to identify patients who will benefit
from treatment with a hypoxia modifiers such as nimorazole during
radiotherapy," lead researcher Jens Overgaard said in a prepared
statement. "By contrast, use of nimorazole was not effective in
patients with low or intermediate plasma concentrations of osteopontin."
[Back]
Delta
launches fight to treat oral cancer in Detroit-(Yahoo News-26/08/2005)
With city as one of top five areas for
disease, dental plan, project team up to encourage tests. A test done with
a device that's essentially a toothbrush can help fight oral cancer -- one
of the stealthiest, deadliest and costliest cancers plaguing minorities in
Metro Detroit. The simple test, called a brush biopsy, can detect oral
cancer long before it takes hold, saving patients' lives and sparing them
costly medical bills. Oral health care experts hope the test will become
as prevalent as mammograms, which have become a key to early detection of
breast cancer.
Many of those most at risk for oral cancer don't know an exam exists,
however. Delta Dental Plans of Michigan and the Detroit Oral Cancer
Prevention Project have teamed up on a regional campaign to encourage
people, especially African-American men, who are at the highest risk for
the disease, to get oral cancer tests."It's a stealth problem that no
one talks about," said Amid Ismail, director of the Detroit Oral
Cancer Prevention Project and University of Michigan professor of
dentistry. "It is unacceptable that the problem of oral cancer is not
publicly known in Detroit."
Oral cancer kills about 30,000 Americans a year and is especially
prevalent in Detroit. The city each year ranks among the top five
metropolitan areas for oral cancer rates. Smoking, drinking alcohol and
exposure to ultraviolet rays are all risk factors for oral cancer. Donald
Jones worried for weeks because his tongue was changing color. The
66-year-old Detroiter decided to get a test, which was negative, after
seeing a billboard about oral cancer. "I had no idea even that oral
cancer existed," Jones said.
During the test, a dentist uses a toothbrush-like device to scrape tissue
from inside a patient's mouth that is then tested for cancer. Delta Dental
Plans of Michigan is spending $50,000 to cover brush biopsies and other
exams and treatments for uninsured Wayne County residents. Patients will
receive a screening from the Detroit Dental Assessment Center. Depending
on the results, patients may then be referred to volunteer dentists.
Okemos-based Delta Dental, which insures 5.1 million people in Michigan,
Ohio and Indiana, is trying to promote tests among dentists, as well. The
insurer is among few that reimburses patients for brush biopsies.If oral
cancer is caught early, the cure is simple removal of diseased tissue. In
later stages, treatment consists of disfiguring surgeries that can cost
more than $200,000. The survival rate drops to 57 percent from 81 percent
when the disease is not detected early.
[Back]
|